Mycenax Biotech Inc.

Mycenax Biotech Inc. is a biotechnology and biopharmaceutical company specializing in contract development and manufacturing organization (CDMO) services for biologics. Founded in 2001 and headquartered in Taiwan, the company provides a comprehensive range of solutions for the development and production of innovative biopharmaceuticals and biosimilars, encompassing small peptides, fusion proteins, monoclonal antibodies, vaccines, multi-specific antibodies, antibody-drug conjugates, plasmid DNA, and cell therapy products. Mycenax offers end-to-end capabilities including cell line development, process optimization, cGMP manufacturing, aseptic fill and finish, and regulatory support, leveraging advanced technology platforms and two PIC/S GMP-compliant facilities to serve clients globally. The firm's product portfolio includes proprietary biologics addressing brain cancer, psoriasis, and renal cell carcinoma, and it maintains a robust in-house pipeline alongside manufacturing services. Mycenax's commitment to quality is reflected in its compliance with international standards such as ICH, EMA, FDA, and PMDA guidelines. Its activities play a vital role in accelerating drug development timelines and supporting both domestic and international pharmaceutical sectors, thereby establishing Mycenax as a key partner for innovative and cost-effective biologic therapies in Asia-Pacific and beyond.